As Gilead Sciences INC (GILD) Stock Declined, Ariel Investments LLC Lifted Its Stake by $6.37 Million

February 21, 2018 - By sdfsdfsdf

Investors sentiment increased to 1.03 in 2017 Q3. Its up 0.10, from 0.93 in 2017Q2. It increased, as 96 investors sold GILD shares while 488 reduced holdings. 127 funds opened positions while 474 raised stakes. 957.62 million shares or 2.06% more from 938.32 million shares in 2017Q2 were reported. Private Ocean Llc accumulated 0.04% or 900 shares. Manning Napier Advisors Ltd Limited Liability Company holds 189,381 shares. Pacad Inv Ltd has 17,801 shares. First Corporation In holds 0.02% or 378 shares in its portfolio. Majedie Asset Management invested in 74,359 shares or 0.49% of the stock. 30,300 are owned by Hennessy Advsrs. Ameritas reported 0.27% stake. Fiduciary Tru has 0.29% invested in Gilead Sciences, Inc. (NASDAQ:GILD) for 117,811 shares. Lpl Ltd invested in 0.08% or 296,784 shares. Valueworks Ltd Limited Liability Company reported 4.14% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD). Nikko Asset Management Americas Incorporated holds 0.02% or 6,000 shares in its portfolio. Commonwealth Fincl Bank Of Australia accumulated 0.22% or 284,030 shares. 2,750 are owned by Aspen Investment Mgmt. Essex Investment Ltd Company has 77,866 shares for 0.86% of their portfolio. Doheny Asset Ca holds 27,046 shares.

Since August 30, 2017, it had 0 insider purchases, and 14 selling transactions for $55.76 million activity. MARTIN JOHN C sold $3.68M worth of Gilead Sciences, Inc. (NASDAQ:GILD) on Tuesday, January 2. The insider Meyers James R sold $8.02 million. 60,000 shares were sold by WILSON GAYLE E, worth $4.68M on Friday, February 9. Shares for $4.40 million were sold by Washington Robin L on Thursday, September 7.

John W. Rogers increased its stake in Gilead Sciences Inc. (GILD) by 3.76% based on its latest 2017Q3 regulatory filing with the SEC. Ariel Investments Llc bought 78,624 shares as the company’s stock declined 8.05% while stock markets rallied. The hedge fund run by John W. Rogers held 2.17M shares of the health care company at the end of 2017Q3, valued at $175.77 million, up from 2.09 million at the end of the previous reported quarter. Ariel Investments Llc who had been investing in Gilead Sciences Inc. for a number of months, seems to be bullish on the $105.97 billion market cap company. The stock increased 0.22% or $0.18 during the last trading session, reaching $81.12. About 135,556 shares traded. Gilead Sciences, Inc. (NASDAQ:GILD) has declined 21.80% since February 21, 2017 and is downtrending. It has underperformed by 38.50% the S&P500.

Ariel Investments Llc, which manages about $8.99B and $8.61 billion US Long portfolio, decreased its stake in Progressive Corp. (NYSE:PGR) by 134,597 shares to 1.13M shares, valued at $54.63M in 2017Q3, according to the filing. It also reduced its holding in The Madison Square Garden Co. by 20,886 shares in the quarter, leaving it with 377,743 shares, and cut its stake in Laboratory Corp. Of America Holdings (NYSE:LH).

More notable recent Gilead Sciences, Inc. (NASDAQ:GILD) news were published by: Seekingalpha.com which released: “Gilead Sciences: Market Psychology Shift Will Last” on January 31, 2018, also Bloomberg.com with their article: “Merck Falls After $2.54 Billion Gilead Verdict Is Tossed” published on February 20, 2018, Nasdaq.com published: “Gilead Sciences Inc. Q4 Profit Retreats” on February 06, 2018. More interesting news about Gilead Sciences, Inc. (NASDAQ:GILD) were released by: Seekingalpha.com and their article: “What Can We Expect From Gilead?” published on January 23, 2018 as well as Seekingalpha.com‘s news article titled: “Gilead Does It Again” with publication date: February 08, 2018.

Gilead Sciences, Inc. (NASDAQ:GILD) Ratings Coverage

Among 30 analysts covering Gilead Sciences (NASDAQ:GILD), 21 have Buy rating, 0 Sell and 9 Hold. Therefore 70% are positive. Gilead Sciences had 124 analyst reports since July 29, 2015 according to SRatingsIntel. The firm has “Outperform” rating given on Wednesday, January 20 by Credit Suisse. BMO Capital Markets maintained Gilead Sciences, Inc. (NASDAQ:GILD) on Wednesday, February 7 with “Hold” rating. The stock of Gilead Sciences, Inc. (NASDAQ:GILD) has “Buy” rating given on Monday, January 29 by Wells Fargo. Mizuho maintained Gilead Sciences, Inc. (NASDAQ:GILD) rating on Monday, February 5. Mizuho has “Buy” rating and $83.0 target. The rating was maintained by Jefferies with “Buy” on Monday, June 12. The stock of Gilead Sciences, Inc. (NASDAQ:GILD) has “Hold” rating given on Friday, April 29 by Maxim Group. The company was downgraded on Friday, October 2 by Morgan Stanley. The firm earned “Outperform” rating on Monday, October 3 by RBC Capital Markets. The stock of Gilead Sciences, Inc. (NASDAQ:GILD) earned “Outperform” rating by Oppenheimer on Tuesday, October 20. Bank of America maintained the stock with “Neutral” rating in Wednesday, February 7 report.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.